putting some big pharma muscle behind the therapy for transthyretin amyloid cardiomyopathy (ATTR CM). The deal includes upfront and near-term payments of $310 million for exclusive marketing ...
Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback